No Data
Jiangsu Hengrui Medicine Gets Drug Registration for Anti-cancer Drugs
Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained pharmaceutical registration certificates for two products.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company received a notification from the National Medical Products Administration (referred to as "National Drug..."
Jiangsu Hengrui Pharmaceuticals (600276.SH): Cumulatively repurchased 0.08% of shares.
On December 2, it was announced that jiangsu hengrui pharmaceuticals (600276.SH) had repurchased a total of 4,936,144 shares through centralized bidding by November 30, 2024, accounting for 0.08% of the company's total share capital. The highest transaction price was 57.01 yuan/share, while the lowest price was 39.00 yuan/share. The total amount paid was 206,951,066.60 yuan (excluding transaction fees).
Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.
With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.
Jiangsu Hengrui Medicine Sees Inclusion of 12 Drugs in National Medical Insurance Catalog; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals (600276.SH): The company's pharmaceuticals are included in the national medical insurance catalog.
On November 28th, Hengrui Pharmaceuticals (600276.SH) announced that, through medical insurance negotiations, Fumag Taijili Ding injection, Otokangzuo capsule, Henggelijing Metformin sustained-release tablets (Ⅰ)(Ⅱ) were first included in the national medical insurance catalog; Fluzopali capsules were added to the national medical insurance catalog under the new indication through the simple renewal rule; Injection of Carirelizumab was successfully renewed and new indications were added to the national medical insurance catalog through the simple renewal rule; Hydroethanesulfonic acid darzile tablets, rivaroxaban tablets, pregabalin sustained-release tablets were successfully renewed through the simple renewal rule and retained in the national medical insurance catalog; Fuamino Henggeliejing tablets renewal.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
